/Press Releases

Forge announces oral presentation on development of novel antibiotics at the 28th annual ECCMID meeting

San Diego, California, April 9, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced that David [...]

2018-04-09T06:55:22+00:00 April 9th, 2018|

Forge Therapeutics to Present at the 2018 Needham & Company Healthcare Conference

-Presentation will focus on Forge’s portfolio of four novel classes of antibiotics to treat deadly ‘superbug’ infections from Gram-negative bacteria- San Diego, California, [...]

2018-03-21T09:31:14+00:00 March 21st, 2018|

Forge Co-founder Presents New Approaches to Treat Infections at the 255th American Chemical Society National Meeting

San Diego, California, March 19, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced that Professor [...]

2018-03-16T11:24:49+00:00 March 19th, 2018|

Forge Therapeutics and collaborators from Evotec and USC present new efficacy data at 2017 Keystone Symposia Conference

-Data demonstrates broad applicability for LpxC inhibitor in Acinetobacter baumannii, a life-threatening respiratory bacteria- LpxC antibiotic is Forge’s flagship program stemming from BLACKSMITH [...]

2017-10-31T01:12:48+00:00 October 31st, 2017|

Forge therapeutics announces participation in upcoming scientific and industry events

San Diego, California, October 24, 2017 – Forge Therapeutics, Inc. (Forge) announced today that the company will be participating in several scientific and [...]

2017-10-24T00:35:50+00:00 October 23rd, 2017|

Forge & Evotec expand strategic alliance with launch of BLACKSMITH Platform to discover novel metalloenzyme inhibitors across broad therapeutic areas

- BLACKSMITH Platform Initially Focused on the Development of Novel Classes of Antibiotics - - Expansion Highlights Significance of US-UK Biotech Partnerships –  [...]

2017-10-12T15:06:06+00:00 October 17th, 2017|

Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum

Forge Therapeutics to participate in antimicrobial resistance panel at 2017 Bio Investor Forum San Diego, California, October 11, 2017 – Forge Therapeutics, Inc., [...]

2017-10-09T16:55:18+00:00 October 11th, 2017|

Forge Therapeutics and Evotec present efficacy data for LpxC Inhibitor in urinary tract, lung, thigh, and abdominal infection models at ASM ESCMID 2017

San Diego, California, September 7, 2017 – Forge Therapeutics, Inc., (Forge) and its strategic alliance partner Evotec AG (Evotec), announced new preclinical data [...]

2017-10-06T18:31:58+00:00 September 7th, 2017|
Load More Posts